2022年COPD主要市场将达到140亿美元

2013年9月4日讯 /生物谷BIOON/ --根据全球领先的制药与医疗保健顾问公司Decision Resources日前发布的一份新报告，目前，慢性阻塞性肺病（COPD）市场由勃林格殷格翰（Boehringer Ingelheim）和辉瑞（Pfizer）的长效毒蕈碱受体拮抗剂（LAMA）思力华（Spiriva）、葛兰素史克（GSK）的长效β2激动剂（LABA）/吸入性糖皮质激素（ICS）Advair、舒利迭（Seretide）、Adoair统治。在2012年，这2大类药物销售额占到了COPD市场的2/3。然而，随着新制剂（尤其是那些能够提供给药优势的新制剂）的上市，这2类药物的合并市场份额将在2022年减少至不到15%。

研究发现，到2022年，美国、欧洲、日本等主要市场中，COPD市场将从2012年的近100亿美元增长至140亿美元。在未来10年中，预计将有5种固定剂量LABA/LAMA组合产品上市，在2022年，这一类新药将共同攫取超过35%的市场份额。在这些新的组合药物中，葛兰素史克/Theravance公司的Anoro、勃林格殷格翰公司的olodaterol/噻托溴铵（tiotropium）有望取得最大的成功，2022年在主要市场中的销售将达到40亿美元。

Anoro是葛兰素史克一个更独特的产品，将是市场上首个LAMA/LABA组合，将与Spiriva竞争，而Spiriva也被称为噻托溴铵，是市场上唯一销售的LAMA。

LABA/LAMA组合药物的临床实验数据持续地证明了这类药物的潜力，这些组合产品将提供2大支气管扩张剂类药物（LABA和LAMA）的便利性，目前，这2类药物（LABA和LAMA）均被推荐为COPD的一线维持治疗选择。

调查结果还显示，GSK/Theravance的COPD新药Breo（美国以外的国家称为Relvar）将表现强劲，并作为另一关键增长驱动力，与LABA/LAMA类药物一起，推动COPD市场的持续增长。Breo/Relvar为每日一次的药物，将成为首个相较于Advair（每日2次）提供给药改善的药物，加上与Advair相媲美的疗效，Breo/Relvar将挑战Advair在所有主要市场中的霸主地位。（生物谷Bioon.com）

英文原文：Novel LABA/LAMA Products Will Capture Greater Market Share than the LABA/ICS or LAMA Drug Classes by 2022

LABA/LAMA Fixed-Dose Combinations Will Achieve Over 35 Percent of COPD Sales in 2022, According to Findings from Decision Resources
—Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of a new drug class that will drive sales through 2022. Currently, the COPD market is dominated by Boehringer Ingelheim/Pfizer’s long-acting muscarinic antagonist (LAMA) Spiriva and GlaxoSmithKline’s long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) Advair/Seretide/Adoair. In 2012, total sales of these two market leaders constituted nearly two-thirds of COPD sales. However, following the launch of new agents, particularly those that offer advantages in dosing, their combined market share will diminish to less than 15 percent in 2022.

The Pharmacor advisory service entitled Chronic Obstructive Pulmonary Disease finds that the market for COPD will increase from nearly $10 billion in 2012 to $14 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Five fixed-dose combination inhalers comprised of a LABA and a LAMA are forecasted to launch over the next ten years and this new drug class will collectively garner over 35 percent market share in 2022. Among these novel combinations, GlaxoSmithKline/Theravance’s Anoro and Boehringer Ingelheim’s olodaterol/tiotropium are expected to experience the greatest success, totaling nearly $4 billion in major-market sales in 2022.

“The clinical trial data for LABA/LAMAs continue to be promising and these combination products will provide the convenience of delivering the two major bronchodilator classes that are recommended as first-line maintenance options in treatment guidelines,” said Decision Resources Senior Director Joanna Kim, M.Ed.

The findings also reveal that GlaxoSmithKline/Theravance’s Breo/Relvar will perform strongly and act as another key growth driver, alongside the LABA/LAMAs, in the COPD market. Breo/Relvar’s once-daily administration will be the first to offer dosing improvement over Advair which, together with efficacy that is comparable to Advair, will challenge Advair’s dominance in all major markets.